Art

J-GLOBAL ID：201702214228883379   Reference number：17A0984184

A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial

骨転移前立腺癌患者におけるゾレドロン酸有無での併用アンドロゲン遮断の第III相多施設無作為化対照試験: ZAPCA試験の結果

Author (20)： KAMBA Tomomi (Kyoto Univ., Kyoto, JPN) ,  KAMOTO Toshiyuki (Univ. Miyazaki, Miyazaki, JPN) ,  MARUO Shinichiro (Translational Res. Informatics Center, KOBE, JPN) ,  KIKUCHI Takashi (Translational Res. Informatics Center, KOBE, JPN) ,  SHIMIZU Yosuke (Kyoto Univ., Kyoto, JPN) ,  NAMIKI Shunichi (Osaki Citizen Hospital, Osaki, JPN) ,  FUJIMOTO Kiyohide (Nara Medical Univ., Kashihara, JPN) ,  KAWANISHI Hiroaki (Osaka Red Cross Hospital, Osaka, JPN) ,  SATO Fuminori (Oita Univ., Oita, JPN) ,  NARITA Shintaro (Akita Univ., Akita, JPN) ,  SATOH Takefumi (Kitasato Univ., Sagamihara, JPN) ,  SAITO Hideo (Tohoku Univ., Sendai, JPN) ,  SUGIMOTO Mikio (Kagawa Univ., Kagawa, JPN) ,  TEISHIMA Jun (Hiroshima Univ., Hiroshima, JPN) ,  MASUMORI Naoya (Sapporo Medical Univ., Sapporo, JPN) ,  EGAWA Shin (Jikei Univ., Tokyo, JPN) ,  SAKAI Hideki (Nagasaki Univ., Nagasaki, JPN) ,  OKADA Yusaku (Shiga Univ. Medical Sci., Otsu, JPN) ,  TERACHI Toshiro (Tokai Univ., Isehara, JPN) ,  OGAWA Osamu (Kyoto Univ., Kyoto, JPN)
Material： International Journal of Clinical Oncology  (Int J Clin Oncol)
Volume： 22  Issue： 1  Page： 166-173  Publication year： Feb. 2017 
JST Material Number： L3966A  ISSN： 1341-9625  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： randomized controlled trial ,...
Semi thesaurus term： multi-center,randomized,controlled study ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0984184&from=J-GLOBAL&jstjournalNo=L3966A") }}

JST classification (4)： Urogenital tumors(=neoplasms)  (GM04000S) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Clinical application of other drugs acting on metabolism  (GW13070T)

Substance index (3)： Bicalutamide ,  Leuprorelin acetate ,  Zoledronate

Reference (24)：

• Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9(Suppl 4):3-13
• Gnant M (2012) Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict? Curr Oncol Rep 14:35-43
• Michaelson MD, Kaufman DS, Lee H et al. (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25:1038-1042
• Saad F, Gleason DM, Murray R et al. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
• Saad F, Gleason DM, Murray R et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882

Terms in the title (9)： 骨転移 ,  前立腺癌 ,  患者 ,  ゾレドロン酸 ,  併用 ,  アンドロゲン遮断 ,  施設 ,  無作為化対照試験 ,  試験